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PCarotid Intima-Media Thickness and
Presence or Absence of Plaque Improves
Prediction of Coronary Heart Disease Risk
The ARIC (Atherosclerosis Risk In Communities) Study
Vijay Nambi, MD,*† Lloyd Chambless, PHD,‡ Aaron R. Folsom, MD,§ Max He, MS,‡ Yijuan Hu, BS,‡
Tom Mosley, PHD, Kelly Volcik, PHD,¶ Eric Boerwinkle, PHD,¶ Christie M. Ballantyne, MD*†
Houston, Texas; Chapel Hill, North Carolina; Minneapolis, Minnesota; and Jackson, Mississippi
Objectives We evaluated whether carotid intima-media thickness (CIMT) and the presence or absence of plaque improved
coronary heart disease (CHD) risk prediction when added to traditional risk factors (TRF).
Background Traditional CHD risk prediction schemes need further improvement as the majority of the CHD events occur in
the “low” and “intermediate” risk groups. On an ultrasound scan, CIMT and presence of plaque are associated
with CHD, and therefore could potentially help improve CHD risk prediction.
Methods Risk prediction models (overall, and in men and women) considered included TRF only, TRF plus CIMT, TRF plus
plaque, and TRF plus CIMT plus plaque. Model predictivity was determined by calculating the area under the
receiver-operating characteristic curve (AUC) adjusted for optimism. Cox proportional hazards models were used
to estimate 10-year CHD risk for each model, and the number of subjects reclassified was determined. Observed
events were compared with expected events, and the net reclassification index was calculated.
Results Of 13,145 eligible subjects (5,682 men, 7,463 women), 23% were reclassified by adding CIMT plus plaque
information. Overall, the CIMT plus TRF plus plaque model provided the most improvement in AUC, which in-
creased from 0.742 (TRF only) to 0.755 (95% confidence interval for the difference in adjusted AUC: 0.008 to
0.017) in the overall sample. Similarly, the CIMT plus TRF plus plaque model had the best net reclassification
index of 9.9% in the overall population. Sex-specific analyses are presented in the manuscript.
Conclusions Adding plaque and CIMT to TRF improves CHD risk prediction in the ARIC (Atherosclerosis Risk In Communities)
study. (J Am Coll Cardiol 2010;55:1600–7) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.075i
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Praditional risk prediction scores such as the Framingham
isk score have proven very useful in identifying persons at risk
or coronary heart disease (CHD), but such risk scores have
imitations. Biomarkers, imaging, and genotypes are being
xamined to try to improve CHD risk prediction (1–6).
Carotid intima-media thickness (CIMT) is a well-
escribed surrogate marker for cardiovascular disease, and
ncreased CIMT has been associated with prevalent and
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5020, N01-HC-55021, and N01-HC-55022 from the NHLBI, Bethesda, Mary- ancident CHD and stroke (7,8). Further, statins, which
educe major adverse cardiovascular events (9), have been
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hown to stabilize and regress CIMT. Although reports
3,4) have suggested that adding CIMT, by improving the
rea under the receiver-operating characteristics curve
and. Dr. Nambi has research collaboration with General Electric. Dr. Ballantyne is
consultant for Abbott, Astra Zeneca, Atherogenics, Bristol-Myers Squibb, KOWA,
etabsis, Merck, Merck-Schering-Plough, Novartis, Pfizer, Reliant, Schering-
lough, Sanofi-Synthelabo, Takeda, and GlaxoSmithKline; has received grant/
esearch support from Abbott, ActivBiotics, AstraZeneca, Gene Logic, GlaxoSmith-
line, Integrated Therapeutics, Merck, Pfizer, Schering-Plough, Sanofi-Synthelabo,
nd Takeda; is on the Speakers’ Bureau for AstraZeneca, GlaxoSmithKline, Merck,
fizer, Reliant, and Merck-Schering-Plough, Schering-Plough; and has received
onorarium from Merck, AstraZeneca, Abbott, GlaxoSmithKline, Merck-Schering-
lough, Novartis, Pfizer, Sanof-Synthelabo, Schering-Plough, and Takeda.
Manuscript received July 13, 2009; revised manuscript received October 30, 2009,
ccepted November 2, 2009.
(
d
r
b
m
e
c
W
p
t
s
M
S
c
b
a
c
s
t
p
(
m
(
b
c
p
U
t
B
I
T
A
s
d
c
c
i
s
i
s
s
e
a
m
a
(
d
t
s
a
b
a
t
0
m
g
A
e
c
c
b
e
d
t
i
t
t
p
p
a
h
w
C
a
S
e
r
A
i
t
p
T
p
b
p
p
b
s
7
a
p
t
y
f
B
(
m
w
w
f
i
i
r
w
C
m
1601JACC Vol. 55, No. 15, 2010 Nambi et al.
April 13, 2010:1600–7 CIMT, Plaque, and Risk StratificationAUC), can improve risk prediction from a clinical
ecision-making standpoint, the ability of a marker to
eclassify an person’s risk group is critical (10).
Furthermore, plaque presence, which has been shown to
e associated with CHD independent of CIMT measure-
ents in several studies (11), has not been adequately
valuated in risk classification especially using contemporary
riteria for evaluating novel cardiovascular risk markers (12).
e investigated whether CIMT and information about the
resence or absence of plaque improves CHD risk predic-
ion in the ARIC (Atherosclerosis Risk In Communities)
tudy.
ethods
ubjects. The ARIC study is an epidemiologic study of
ardiovascular disease incidence that recruited a population-
ased cohort of 15,792 subjects between 45 and 64 years of
ge from 4 U.S. communities between 1987 and 1989. A
omplete description of the study design, objectives, and
ampling strategy have been previously described (13). For
his analysis, we excluded patients with prevalent CHD or
revalent stroke (n  763), missing prevalent CHD data
n  339), missing CIMT or plaque data (n  909),
issing information on traditional CHD risk factors (TRF)
n  533), races other than black or white (n  48), and
lack participants from the Minnesota or Washington field
enter (n  55), providing us with a sample of 13,145
atients for the analysis.
ltrasound measurement. The ultrasound procedure in
he ARIC study has been previously described (14–17).
riefly, a Biosound 2000 (Biosound, Indianapolis, Indiana)
ISA system was used and images recorded on a VHS tape.
he CIMT was measured centrally by trained readers at the
RIC Ultrasound Reading Center and was assessed in 3
egments: the distal common carotid (1 cm proximal to
ilation of the carotid bulb), the carotid artery bifurcation (1
m proximal to the flow divider), and the proximal internal
arotid arteries (1 cm section of the internal carotid artery
mmediately distal to the flow divider). At each of these
egments, 11 measurements of the far wall (in 1-mm
ncrements) were attempted. The mean of the mean mea-
urements across these segments of both the right and the left
ides was estimated. Trained readers adjudicated plaque pres-
nce or absence if 2 of the following 3 criteria were met:
bnormal wall thickness (defined as CIMT1.5 mm), abnor-
al shape (protrusion into the lumen, loss of alignment with
djacent arterial wall boundary), and abnormal wall texture
brighter echoes than adjacent boundaries) (11,15). The repro-
ucibility and variation of CIMT and plaque measurements in
he ARIC study have been previously published (15,18). The
ite-specific reliability coefficients was estimated as 0.77, 0.73,
nd 0.70 for the mean carotid far wall IMT at the carotid
ifurcation, internal carotid arteries, and common carotid
rteries, respectively. For the presence or absence of plaque,
he intra-reader agreement was associated with a  statistic of o.76, and the inter-reader agree-
ent was 0.56, which suggests
ood agreement beyond chance.
scertainment of incident CHD
vents. Incident CHD events in-
luded definite or probable myo-
ardial infarction (MI), silent MI
etween examinations indicated by
lectrocardiograms, definite CHD
eath, or coronary revasculariza-
ion. The methods by which the
ncident CHD events were ascer-
ained and classified and the de-
ails of quality assurance have been
reviously published (19). Briefly,
articipants were contacted annu-
lly, and discharge lists from local
ospitals and death certificates
ere surveyed to look for incident
HD events. Follow-up for this
nalysis was until December 31, 2005.
tatistical analysis. The analyses were performed in the
ntire study sample and then by sex. The ARIC coronary
isk score (ACRS), developed by Chambless et al. (4) in the
RIC cohort, is similar to the Framingham risk score and
ncludes age, age2, sex, systolic blood pressure, antihyper-
ensive medication use, total cholesterol, high-density li-
oprotein cholesterol, diabetes mellitus, and smoking status.
he ACRS variables were used in the “TRF only” risk
rediction model in our analysis, as it would represent the
est TRF-based model in the ARIC study for CHD
rediction. However, we also evaluated adding CIMT and
laque to a Framingham risk score (FRS)-based TRF model
ecause the FRS is traditionally used by most clinicians.
Several models were considered: 1) TRF plus (sex-
pecific) CIMT, categorized as 25th percentile, 25th to
5th percentile, and 75th percentile; 2) TRF plus plaque;
nd 3) TRF plus CIMT (sex-specific and categorized as
reviously stated) plus plaque. We described the area under
he receiver-operating characteristic curve (AUC) for 10-
ear risk using methods that accounted for censoring (20)
or each of the models to describe the model predictivity.
ootstrapping was performed to obtain confidence intervals
CI) for the differences in adjusted AUC between the
odels and to adjust for the overoptimism that can occur
hen the fit of the model is tested using the same data in
hich it was described (21–23).
Using Cox proportional hazards, the 10-year CHD risk
or each of the models was calculated, and subjects classified
nto 0% to 5% risk (low risk), 5% to 10% risk (low-
ntermediate risk), 10% to 20% risk (intermediate-high
isk), and 20% risk (high risk). The number of subjects
ho changed risk groups (i.e., reclassified after adding
IMT and plaque data) was then described. To test the
odel calibration, we compared the goodness-of-fit of the
Abbreviations
and Acronyms
ACRS  ARIC coronary risk
score
AUC  area under the
receiver-operating
characteristic curve
CHD  coronary heart
disease
CI  confidence interval
CIMT  carotid intima-
media thickness
IDI  integrated
discrimination improvement
MI  myocardial infarction
NRI  net reclassification
index
TRF  traditional risk
factorsbserved and expected number of events within estimated
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CIMT, Plaque, and Risk Stratification April 13, 2010:1600–7isk decile groups using the Grønnesby-Borgan statistic
24). Large values of the test statistic (i.e., significant
values) suggest poor model fit. We then calculated the net
eclassification index (NRI), which examines the net effect
f adding a marker to the risk prediction scheme using a
tatistic described by Pencina et al. (25), except estimated by
method accounting for censoring (Dr. Lloyd Chambless,
ersonal communication, 2009). We also described the
linical NRI, or the NRI in the groups defined as interme-
iate risk (5% to 10% and 10% to 20% estimated CHD risk
ased on the model before reclassification), namely, the
roups in which the addition of a marker may be of most use.
inally, we also estimated the integrated discrimination im-
rovement (IDI) (25) (again accounting for censoring), which
s the difference in an R2-like statistic between the traditional
nd expanded models. The AUC, NRI, and IDI were calcu-
ated for 10-year follow-up and, confidence intervals were
urnished by bootstrapping.
esults
he study sample’s baseline characteristics are listed in
able 1. The 25th and 75th percentile CIMT of the 5,682
en and 7,463 women (n  13,145) were 0.65 mm and
.84 mm for men and 0.58 mm and 0.74 mm for women,
espectively. Atherosclerotic plaque presence increased from
3.6% in the overall population with a CIMT 25th
ercentile (17.4% in men, 10.7% in women), to 26.2% in
hose with a CIMT between the 25th and 75th percentile
33.5% for men and 20.7% for women), and to 65.3% in
hose with a CIMT 75th percentile (73.1% in men and
9.5% in women). When evaluated by risk groups, plaque
Baseline Characteristics After Exclusions: ARICTable 1 Baseline Characteristics After Excl
M
(n 
Age, yrs 54.4
Body mass index, kg/m2 27.2
Systolic blood pressure, mm Hg 122.
Diastolic blood pressure, mm Hg 75.
Total cholesterol, mg/dl 210.
Triglycerides, mg/dl 130.
HDL cholesterol, mg/dl 45.
LDL cholesterol, mg/dl 138.
CIMT 25th percentile (unadjusted), mm
CIMT 75th percentile (unadjusted), mm
Fasting glucose, mg/dl 106.
Whites 77
Diabetes mellitus 10
Current tobacco use 27
Former tobacco use 43
Cholesterol-lowering medication use 2
Aspirin use (%) 41
Statin use (%) 0Data shown as mean (SD) or prevalence %.
CIMT  carotid intima-media thickness; HDL  high-density lipoprotein; LDrevalence increased from 24% in the 0% to 5% risk group
o 34.3% in the 5% to 10% risk group, 46.5% in the 10% to
0% risk group, and 54.6% in the20% risk group, 10-year
HD (high) risk groups.
Over a mean follow-up period of 15.1 years (men  14.4
ears, women  15.7 years), there were 1,812 incident
HD events (867 definite or probable MI, 159 CHD
eaths, 688 coronary revascularizations, and 98 silent
electrocardiography-confirmed] MI).
When examining the AUC, adding CIMT and/or plaque
nformation (individually and together) to TRF improved
he AUC significantly (even after adjustment for optimism)
n both men and women, except that adding CIMT alone in
omen was not significant (Table 2).
Adding plaque to TRF had a more pronounced effect
han adding CIMT to TRF on the AUC in women. In
omen, the AUC increased from 0.759 (TRF alone) to
.762 (95% CI for the difference in adjusted AUC: 0.002
o 0.006) when CIMT was added to TRF, whereas the
UC increased to 0.770 (95% CI for the difference in
djusted AUC: 0.005 to 0.016) for plaque alone plus TRF.
he TRF plus CIMT plus plaque model was associated
ith a similar AUC of 0.770 (95% CI: 0.005 to 0.017).
onversely, adding CIMT had a more pronounced effect
han adding plaque to TRF on the AUC for men. For men,
he AUC increased from 0.674 (TRF alone) to 0.690 (95%
I for the difference in adjusted AUC: 0.009 to 0.022)
hen CIMT was added to TRF while the AUC increased
o 0.686 (95% CI: 0.005 to 0.017) for plaque alone plus
RF. The TRF plus CIMT plus plaque model was associ-
ted with the most increase in AUC, which increased to
.694 (95% CI: 0.011 to 0.027). When we considered the
y, 1987 to 1989s: ARIC Study, 1987 to 1989
)
Women
(n  7,463)
Entire Sample
(n  13,145)
53.75 (5.7) 54.0 (5.8)
27.46 (5.8) 27.36 (5.1)
) 119.7 (19.1) 120.72 (18.6)
) 71.9 (10.9) 73.46 (11.2)
) 217.0 (42.1) 214.0 (41.1)
) 117.1 (60.5) 122.9 (63.7)
) 58.2 (17.2) 52.6 (17.1)
) 135.4 (40.2) 136.8 (39.0)
0.58 0.61
0.74 0.78
) 104.1 (32.6) 105.0 (30.7)
72.6% 74.8%
10.0% 10.1%
25.0% 26.1%
22.48% 31.5%
2.6% 2.4%
49.4% 45.8%
0.6% 0.5%Studusion
en
5,682
2 (5.8)
3 (4.0)
1 (17.7
5 (11.2
2 (39.4
4 (67.0
3 (13.9
8 (37.2
0.65
0.84
3 (28.0
.7%
.3%
.6%
.2%
.3%
.1%
.3%L  low-density lipoprotein.
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April 13, 2010:1600–7 CIMT, Plaque, and Risk Stratificationddition of plaque to a model that included TRF plus
IMT, it significantly improved the AUC in women by
.009 (95% CI: 0.003 to 0.012), whereas in men, the
ncrease in AUC by 0.004 (95% CI: 0.001 to 0.006) was
onsignificant. Conversely, when we considered the addi-
ion of CIMT to a model that included TRF plus plaque, it
mproved the AUC in men by 0.008 (95% CI: 0.002 to
.011), but in women, the increase in AUC by 0.000 (95%
I: 0.002 to 0.002) was nonsignificant.
The CHD incidence rate per 1,000 person years in the
arious CIMT categories taking into account the presence
r absence of plaque is described in Figure 1. In all CIMT
ategories, the presence of plaque was associated with a
igher incidence of CHD events.
Adding plaque information along with CIMT to TRF
esulted in the reclassification of 8.6%, 37.5%, 38.3%, and
1.5% of the overall sample in the5%, 5% to 10%, 10% to
0%, and 20% 10-year estimated risk groups, respectively
Table 3); and adding plaque and CIMT reclassified 17.4%,
2.8%, 36.6%, and 25.2% of the men (Table 4) and 5.1%,
0.2%, 38.4%, and 24.9% of the women (Table 5) in the same
Adjusted AUC for Different Models, With 95% CDifference in Adjusted AUC C mparing Various MTable 2 Adjusted AUC for Diffe ent Model ,Difference in Adjusted AUC Compar
Model Overall
TRF only 0.742
TRFCIMT 0.750 (0.005 to 0.
TRFplaque 0.751 (0.006 to 0.
TRFCIMTplaque 0.755 (0.008 to 0.
TRFCIMTplaque vs. TRFIMT (0.001 to 0.006
TRFIMTplaque vs. TRFplaque (0.001 to 0.005
AUC  area under the curve; CI  confidence interval; CIMT  carotid
7.2
13.2 12
4.6
9
7.6
2.9
6.1 4.4
8
0
5
10
15
20
25
CIMT<25th
percentile, no
plaque
CIMT<25th
percentile, yes
plaque
CIMT25-75
percentile, no
plaque
CIMT
percen
pla
Figure 1 Adjusted Coronary Heart Disease Incidence Rate per
1,000 Person-Years Adjusted by CIMT Categories Wit
For every carotid intima-media thickness (CIMT) category (i.e., 25th percentile, 2
(green bars), men (yellow bars), or women (orange bars), having carotid artery plisk groups. Overall, more subjects were reclassified to a lower
isk group (12.4%) than to a higher risk group (10.8%),
nd nobody was reclassified from the low-risk group (5%
stimated 10-year CHD risk) to the high-risk group (20%,
0-year estimated CHD risk) or vice versa.
We then examined the goodness-of-fit of the various
odels using the Grønnesby-Borgan statistic. When the
verall population was considered, although model fit im-
roved with the addition of CIMT and/or plaque, none of the
odels had a good fit with the chi-square statistic (p value)
eing 30.0 (p  0.0004), 23.7 (p  0.005), and 24.3 (p 
.004) for the TRF only model, TRF plus CIMT model, and
RF plus CIMT plus plaque model, respectively. When men
nd women were considered separately, the model fit im-
roved. In men, the CIMT plus TRF model was the best fit
chi-square statistic 14.12, p 0.11), while the CIMT plus
RF plus plaque model and the TRF-only model were not as
ood fits (chi-square statistic 17.9 [p 0.04] and 18.7 [p
.028], respectively). Conversely, in women, the chi-square test
tatistics were 15.0 (p  0.09), 9.1 (p  0.43), and 8.7 (p 
.47) for the TRF only, TRF plus CIMT and TRF plus
nce Interval forls With TRF-Only Model95% Confidence Interval for
arious Models With TRF-Only Model
Men Women
0.674 0.759
0.690 (0.009 to 0.022) 0.762 (0.002 to 0.006)
0.686 (0.005 to 0.017) 0.770 (0.005 to 0.016)
0.694 (0.011 to 0.027) 0.770 (0.005 to 0.017)
(0.001 to 0.006) (0.003 to 0.012)
(0.002 to 0.011) (0.002 to 0.002)
-media thickness; TRF  traditional risk factors.
15.6
18.2
24.7
11
11.7
17
7.1
11.4
CIMT>75
percentile,no
plaque
CIMT>75
percentile yes
plaque
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Overall
Men
,
Without Plaque
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CIMT, Plaque, and Risk Stratification April 13, 2010:1600–7IMT plus plaque models, respectively, which suggested that the
RF plus CIMT plus plaque model had the best model fit.
Finally, we examined the NRI and the clinical NRI (NRI
n the intermediate groups). We compared several models
Table 6) and found that the TRF plus CIMT plus plaque
odel was better than the TRF-only model in the overall
ample, in men, and in women. However, adding plaque
ata minimally affected the TRF plus CIMT model in men,
hile adding CIMT information minimally affected the
RF plus plaque model in women. Overall, the TRF plus
IMT plus plaque model when compared to the TRF-only
odel was associated with an NRI of 9.9% (clinical NRI
1.7%) in the overall sample, 8.9% (clinical NRI 16.4%)
hen men were considered separately, and 9.8% (clinical
RI 25.4%) when women were considered separately,
uggesting effective reclassification. The IDI showed that
he model predictivity was significantly improved by adding
IMT and plaque to TRF: in the overall population, the
DI was 0.011; in women, it was 0.009; and, in men, it was
.013 (Online Table).
When we added CIMT and plaque information to a
RS-based TRF model, the results were similar. The
umber and Percent Reclassified in CHD Risk Categories and Obsehen CIMT and Plaque Informatio Are Added to Traditional Risk PTable 3 Number and Pe cent Reclassified in CHD Ri k CategorWhen CIMT and Plaque Information Are Added to Trad
CHD Risk by TRF Only <5% 5%–1
5%, low risk 5,585 (91.4) 523 (8
2 5
5%–10%, low-intermediate risk 839 (22.4) 2,340 (6
5 7
10%–20%, high-intermediate risk 0 (0.00) 627 (2
— 11
20%, high risk 0 (0.00) 0 (0
— —
All 6,264 (48.9) 3,490 (2
2 7
alues are n (%) and Kaplan-Meier 10-year risk (%). *All observed risks have been interpolated to 1
f 15.1 years.
umber and Percent Reclassified in CHD Risk Categories and Obsehen CIMT and Plaque Informatio Are Added to Traditional Risk PTable 4 Number and Pe cent Reclassified in CHD Ri k CategorWhen CIMT and Plaque Information Are Added to Trad
CHD Risk by TRF Only <5% 5%–10%
5%, low risk 563 (82.6) 119 (17.5
2 2
5%–10%, low-intermediate risk 338 (16.0) 1,419 (67.2
5 7
10%–20%, high-intermediate risk 0 (0.00) 526 (23.6
— 11
20%, high risk 0 (0.00) 0 (0.00
— —
All 901 (15.9) 2,064 (36.3
3 8alues are n (%) and Kaplan-Meier 10-year risk (%). *All observed risks have been interpolated to 10-year e
f 14.4 years.djusted AUC in men and women using the FRS model
lone were 0.661 and 0.741, respectively, and improved to
.685 (95% CI for the difference in adjusted AUC: 0.014 to
.032) and 0.751 (95% CI for the difference in adjusted
UC: 0.003 to 0.016), respectively, by adding CIMT and
laque. In men, 11.5%, 34%, 37.9%, and 32% of those in
he 5%, 5% to 10%, 10% to 20%, and 20% FRS
ategories, respectively, were reclassified by adding CIMT
nd plaque, resulting in a NRI of 12.7% and a clinical NRI
f 18.9%. However, in women, 6.6%, 41%, 39.8% and
6.3% of those in the 5%, 5% to 10%, 10% to 20%, and
20% FRS categories, respectively, were reclassified, result-
ng in a NRI of 7.7% and a clinical NRI of 21.2%. Finally,
hen the goodness-of-fit was tested using the Grønnesby-
organ test statistic, the model with FRS plus CIMT plus
laque was better than the FRS-only model in both men
chi-square statistic for FRS only  15.05, p  0.09;
hi-square statistic for FRS plus CIMT plus plaque 
0.18, p  0.34) and women (chi-square statistic for FRS
nly  8.63, p  0.47; chi-square statistic for FRS plus
IMT plus plaque  4.97, p  0.84).
CHD Risk*tion Models (Overall Sample)nd Observ d CHD Risk*
l Risk Prediction Models (Overall Sample)
CHD Risk by TRF  CIMT  Plaque
10%–20% >20% All
0 (0.00) 0 (0.00) 6,108 (46.5)
— — 2
563 (15.1) 0 (0.00) 3,742 (28.5)
17 — 8
1,560 (61.7) 340 (13.5) 2,527 (19.2)
15 24 15
165 (21.5) 603 (78.5) 768 (5.8)
14 31 27
2,288 (17.4) 943 (7.2) 13,145 (100.0)
15 28 7
vent rates by Kaplan-Meier risk estimates using the actual observed events over a mean follow-up
CHD Risk*tion Models (Men)nd Observ d CHD Risk*
l Risk Prediction Models (Men)
HD Risk by TRF  CIMT  Plaque
10%–20% >20% All
0 (0.00) 0 (0.00) 682 (12.0)
— — 2
355 (16.8) 0 (0.00) 2,112 (37.2)
13 — 8
1,413 (63.4) 290 (13.0) 2,229 (39.2)
14 24 15
166 (25.2) 493 (74.8) 659 (11.6)
16 31 27
1,934 (34.0) 783 (13.8) 5,682 (100.0)
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April 13, 2010:1600–7 CIMT, Plaque, and Risk Stratificationiscussion
lthough CHD risk prediction models based on “traditional
isk factors” have formed the basis for the clinical practice of
HD prevention, they are far from optimal (26). Several
fforts have looked at adding biomarkers to improve cardiovas-
ular risk prediction (1,2), and other recent efforts have examined
he use of genetic markers as well (5). Of these, high-sensitivity
-reactive protein has shown the most promise.
Imaging tests such as carotid artery ultrasonography and
oronary calcium score offer another marker that could be used
n improving CHD risk prediction by directly visualizing
therosclerosis. Although several efforts have examined the use
f these imaging modalities, there are limited data using
ontemporary statistical methodology that have evaluated
hether the addition of imaging markers to risk models can
mprove risk prediction. Furthermore, most of the studies
xamining CIMT have had limited CHD events in follow-up
nd did not utilize information about plaque presence or absence.
We now show that, for the 13,145 ARIC participants
ollowed up for 15 years, using CIMT and plaque informa-
ion can improve CHD risk prediction. Adding CIMT and
laque information resulted in the reclassification of 23% of
he subjects, with a net reclassification improvement of9.9%.
owever, it must be noted that more subjects were reclassified
o a lower risk group than to a higher risk group. Almost 61.9%
f those reclassified from the intermediate risk group (5% to
umber and Percent Reclassified in CHD Risk Categories and Obsehen CIMT and Plaque Informatio Are Added to Traditional Risk PTable 5 Number and Pe cent Reclassified in CHD Ri k CategorWhen CIMT and Plaque Information Are Added to Trad
CHD Risk by TRF Only <5% 5%–10%
5%, low risk 5,305 (94.9) 287 (5.1)
2 6
5%–10%, low-intermediate risk 316 (26.9) 704 (59.8
5 9
10%–20%, high-intermediate risk 0 (0.00) 132 (25.3
— 6
20%, high risk 0 (0.00) 0 (0.00
— —
All 5,621 (75.3) 1,123 (15.1
2 8
alues are n (%) and Kaplan-Meier 10-year risk (%). *All observed risks have been interpolated to 1
f 15.7 years.
CHD  coronary heart disease; other abbreviations as in Table 2.
RI Using Various Comparison Models in Overall Sample, Men, andTable 6 NRI Using Various Comparison Models in Overall Samp
Model
Overall
NRI Clinical NRI
TRF vs. TRF  CIMT 7.1 (2.2 to 10.6) 16.7 (9.3 to 22.4)
TRF vs. TRF  plaque 7.7 (2.3 to 11.4) 17.7 (10.9 to 24.7)
TRF vs. TRF  CIMT  plaque 9.9 (3.8 to 13.5) 21.7 (13.4 to 28.2)
TRF  CIMT vs. TRF  CIMT  plaque 2.8 (1.2 to 6.4) 10.6 (3.8 to 16.5)
TRF  plaque vs. TRF  CIMT  plaque 2.1 (1.1 to 5.3) 7.9 (2.6 to 13.3)alues are % (95% confidence interval).
NRI  net reclassification index; other abbreviations as in Table 2.0% estimated 10-year CHD risk) were reclassified to lower
isk. Furthermore, nobody from the low-risk group was reclas-
ified to a high-risk group, and nobody from the high-risk
roup was reclassified to the low-risk group.
Plaque presence seemed to have a more profound effect on
mproving risk prediction in women than in men, and it is not
ompletely clear why. There are likely several possible expla-
ations. One possible explanation, perhaps, is that since
iddle-aged women have a relatively low prevalence of ath-
rosclerosis, plaque presence, which reflects a definite area of
therosclerosis, was more powerful than using a sex-specific
ercentile “thickness” (CIMT). Similarly, given the overall
ower prevalence of atherosclerosis in women, it is possible that
CIMT 75th percentile misclassifies subjects without ath-
rosclerosis as higher risk, and a specific CIMT cutpoint may
e better in women. However, it is clear that when one
onsiders the intermediate risk groups, the groups for which one
ould advocate further risk stratification, adding plaque and
IMT data best improved risk prediction in men and women.
Overall, the NRI and clinical NRI (9.9% and 21.7%,
espectively, in the overall sample population when the TRF
lus CIMT plus plaque model was compared to the TRF-only
odel) was similar to other recent strategies that have been
sed in improving risk prediction (2,25).
Coronary calcium score is another imaging test used in
linical practice to identify higher risk subjects. A recent
CHD Risk*tion Models (Women)nd Observ d CHD Risk*
l Risk Prediction Models (Women)
HD Risk by TRF  CIMT  Plaque
10%–20% >20% All
0 (0.00) 0 (0.00) 5,592 (74.9)
— — 2
157 (13.3) 0 (0.00) 1,177 (15.8)
12 — 8
321 (61.6) 68 (13.1) 521 (7.0)
14 32 14
43 (24.9) 130 (75.1) 173 (2.3)
8 37 30
521 (7.0) 198 (2.7) 7,463 (100.0)
3 35 4
vent rates by Kaplan-Meier risk estimates using the actual observed events over a mean follow-up
enen, and Women
Men Women
NRI Clinical NRI NRI Clinical NRI
(3.4 to 15.1) 15.8 (8.6 to 24.6) 6.1 (2.3 to 9.4) 15.9 (1 to 23.3)
(0.2 to 12.2) 10.5 (4.5 to 20.5) 10.2 (0.7 to 15.4) 25.6 (7.8 to 37.6)
(4.1 to 17.1) 16.4 (9.5 to 27) 9.8 (1.1 to 15.4) 25.4 (9 to 37)
(2.6 to 6.3) 5.1 (0.3 to 13.2) 3.6 (1.7 to 11.6) 12.8 (2.5 to 28.6)
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CIMT, Plaque, and Risk Stratification April 13, 2010:1600–7tudy reported that coronary calcium score was a better
redictor of incident cardiovascular events, especially CHD
vents, when compared to CIMT (6). However, this study
id not consider plaque presence or absence. Furthermore,
he overall number of incident cardiovascular disease events
as only 222, including angina, and the follow-up was
horter. Other reports comparing the 2 modalities have
ielded mixed results (27,28). Hence, a more long term
omparison of coronary calcium scores with CIMT plus
laque in the prediction of cardiovascular risk will be
nstructive. In addition, several other factors including
ost-effectiveness and safety and feasibility of testing will all
eed to be considered in identifying the role these imaging
ests may have in risk stratification.
Finally, although current guidelines (29) suggest that sub-
ects with a 0% to 10% predicted 10-year risk should be
onsidered “low” in risk, reports suggest that there is a
pectrum of risk in the 0% to 10% risk group, and therefore 5%
o 20% 10-year estimated risk should be considered the
intermediate” risk group (1,30,31). Therefore, we divided the
% to 10% risk group into 0% to 5% (low risk) and 5% to 10%
low-intermediate risk) estimated risk groups. Plaque preva-
ence was almost 10% higher in the 5% to 10% risk group
34% prevalence) when compared to the 0% to 5% predicted
isk group (24% prevalence).
In summary, our data suggest that CIMT and plaque
nformation can be used to improve CHD risk prediction,
nd that the improvement in risk prediction may be equiv-
lent or superior to other contemporary markers.
In the future, further improvement in our ability to
tratify CHD risk may be possible through reliable quanti-
cation of plaque volume, as the mere presence of plaque
ithout any quantification helped improve overall CHD
isk prediction in our analysis.
The strengths of our study include the use of contemporary
tatistical methodology (12), the long-term follow-up, and the
umber of incident CHD events accrued over the period.
urthermore, we examined the ability of CIMT and plaque to
mprove risk prediction when added to both the ACRS- and
RS-based TRF models. Finally, diabetes is included in the
CRS-based TRF model; although this is considered a CHD
isk equivalent, we chose to include diabetes in the model to
valuate whether adding CIMT and plaque can improve the
est CHD prediction model in the ARIC study.
tudy limitations. We used data from the ARIC study’s
aseline visit for this analysis. We have not accounted for
hanges in the risk factors over the period of this analysis or
hanges in the medications during this time. However, this
s similar to any risk prediction scheme that has been
escribed. Recent data (32) suggest that persons with an
ncreased lifetime risk may have a higher burden of subclin-
cal atherosclerosis. We did not consider lifetime risk, but
dding CIMT and plaque data helped to better identify
eople at short-term risk and, hence, may have additional
alue over the estimation of lifetime risk. We did not
ccount for the potential difference between plaque presencen 1 artery alone versus in multiple arteries. It is possible that
laque presence in multiple carotid artery segments may be
ssociated with a higher risk. Several subjects (n 909) had
issing CIMT data, and we do not know how their
resence in the study would have impacted the results.
inally, at this time, there is no clinical study evidence that
hows whether treating subjects by this strategy based on the
dentification of higher risk will prevent incident cardiovas-
ular events, although one would expect that to be the case.
onclusions
arotid ultrasound-based CIMT measurement and identi-
cation of plaque presence or absence improves CHD risk
rediction in the ARIC study and should be considered in
he intermediate risk group (5% to 20% estimated 10-year
HD risk). Ultrasound-based risk stratification strategies
hould be tested in clinical trials to evaluate whether
mproved prevention of cardiovascular events is possible. A
HD risk calculator based on adding CIMT and plaque to
RF as described in this manuscript is available online at
ww.ARICnews.net.
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